{"protocolSection":{"identificationModule":{"nctId":"NCT00148798","orgStudyIdInfo":{"id":"EMR 62202-046"},"organization":{"fullName":"Merck KGaA, Darmstadt, Germany","class":"INDUSTRY"},"briefTitle":"Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)","officialTitle":"Open, Randomized, Controlled, Multicenter Phase III Study Comparing Cisplatin/Vinorelbine Plus Cetuximab Versus Cisplatin/Vinorelbine as First-line Treatment for Patients With Epidermal Growth Factor Receptor Expressing (EGFR-expressing) Advanced NSCLC.","acronym":"FLEX"},"statusModule":{"statusVerifiedDate":"2014-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2004-10"},"primaryCompletionDateStruct":{"date":"2007-07","type":"ACTUAL"},"completionDateStruct":{"date":"2012-05","type":"ACTUAL"},"studyFirstSubmitDate":"2005-09-07","studyFirstSubmitQcDate":"2005-09-07","studyFirstPostDateStruct":{"date":"2005-09-08","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-08-24","resultsFirstSubmitQcDate":"2011-08-24","resultsFirstPostDateStruct":{"date":"2011-10-04","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-06-13","lastUpdatePostDateStruct":{"date":"2014-06-25","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck KGaA, Darmstadt, Germany","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior chemotherapy. Overall survival will be taken as primary measure of efficacy."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer (NSCLC)"],"keywords":["Cetuximab","Non small cell lung cancer","Lung cancer","Cisplatin/vinorelbine","Monoclonal antibody","Erbitux"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":1861,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cetuximab plus chemotherapy","type":"EXPERIMENTAL","description":"cetuximab + cisplatin + vinorelbine","interventionNames":["Drug: cetuximab + cisplatin + vinorelbine"]},{"label":"Chemotherapy alone","type":"ACTIVE_COMPARATOR","description":"cisplatin + vinorelbine alone","interventionNames":["Drug: cisplatin + vinorelbine"]}],"interventions":[{"type":"DRUG","name":"cetuximab + cisplatin + vinorelbine","description":"cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\\^2 initial dose and 250mg/m\\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.","armGroupLabels":["Cetuximab plus chemotherapy"]},{"type":"DRUG","name":"cisplatin + vinorelbine","description":"cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.","armGroupLabels":["Chemotherapy alone"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival Time (OS)","description":"Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.","timeFrame":"Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007"}],"secondaryOutcomes":[{"measure":"Progression-free Survival Time","description":"Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause.\n\nOnly deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.","timeFrame":"Time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007"},{"measure":"Best Overall Response Rate","description":"The best overall response rate is defined as the proportion of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).","timeFrame":"Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007"},{"measure":"Disease Control Rate","description":"The disease control rate is defined as the proportion of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria).","timeFrame":"Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007"},{"measure":"Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status","description":"Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.","timeFrame":"at baseline, at cycle 3, at month 6, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007"},{"measure":"Quality of Life Assessment (EORTC QLQ-C30) Social Functioning","description":"Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.","timeFrame":"at baseline, at cycle 3, at month 6, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007"},{"measure":"A Population Pharmacokinetic (PK) Analysis for Cetuximab in Non-Small Cell Lung Cancer (NSCLC) - Serum Cetuximab Concentrations","description":"Population PK analysis was conducted using non-linear mixed effects modeling (NONMEM) software, integrating the PK data from this study and the Phase II study EMR 62 202-011.","timeFrame":"Week 1, Day 1: baseline and end of infusion; Week 7, Day 43: within 12 h after cetuximab administration."},{"measure":"Safety - Number of Patients Experiencing Any Adverse Event","description":"Please refer to Adverse Events section for further details","timeFrame":"time from first dose up to 30 after last dose of study treatment, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of histologically or cytologically confirmed NSCLC, stage IIIb with documented malignant pleural effusion or stage IV\n* Immunohistochemical evidence of EGFR expression on tumor tissue\n* Presence of at least 1 bi-dimensionally measurable index lesion, whereby index lesions must not lie in an irradiated area\n\nExclusion Criteria:\n\n* Previous exposure to monoclonal antibodies, signal transduction inhibitors or EGFR-targeting therapy\n* Previous chemotherapy for NSCLC\n* Documented or symptomatic brain metastasis\n* Superior vena cava syndrome contra-indicating hydration\n* Previous malignancy in the last 5 years except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Robert Pirker, Professor","affiliation":"Universitätsklinik für Innere Medizin I, Wien","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Research Site","city":"Buenos Aires","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Research Site","city":"Córdoba","country":"Argentina","geoPoint":{"lat":-31.40648,"lon":-64.18853}},{"facility":"Research Site","city":"Adelaide","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"Research Site","city":"Melbourne","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Research Site","city":"Randwick","country":"Australia","geoPoint":{"lat":-33.91439,"lon":151.24895}},{"facility":"Research Site","city":"Sydney","country":"Australia","geoPoint":{"lat":-33.86785,"lon":151.20732}},{"facility":"Research Site","city":"Wodonga","country":"Australia","geoPoint":{"lat":-36.12179,"lon":146.88809}},{"facility":"Research Site","city":"Vienna","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Research Site","city":"Brussels","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Research Site","city":"Charleroi","country":"Belgium","geoPoint":{"lat":50.41136,"lon":4.44448}},{"facility":"Research Site","city":"Liège","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"Research Site","city":"Porto Alegre","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Research Site","city":"São Paulo","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Research Site","city":"Pleven","country":"Bulgaria","geoPoint":{"lat":43.41791,"lon":24.61666}},{"facility":"Research Site","city":"Sofia","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Research Site","city":"Stara Zagora","country":"Bulgaria","geoPoint":{"lat":42.43205,"lon":25.64262}},{"facility":"Research Site","city":"Veliko Tarnovo","country":"Bulgaria","geoPoint":{"lat":43.08124,"lon":25.62904}},{"facility":"Research Site","city":"Antofagasta","country":"Chile","geoPoint":{"lat":-23.65094,"lon":-70.39752}},{"facility":"Research Site","city":"Santiago","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Research Site","city":"Brno","country":"Czechia","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Research Site","city":"Ostrava","country":"Czechia","geoPoint":{"lat":49.83465,"lon":18.28204}},{"facility":"Research Site","city":"Pilsen","country":"Czechia","geoPoint":{"lat":49.74747,"lon":13.37759}},{"facility":"Research Site","city":"Prague","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Research Site","city":"Brest","country":"France","geoPoint":{"lat":48.39029,"lon":-4.48628}},{"facility":"Research Site","city":"Caen","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"Research Site","city":"Grenoble","country":"France","geoPoint":{"lat":45.17869,"lon":5.71479}},{"facility":"Research Site","city":"Marseille","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Research Site","city":"Paris","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Research Site","city":"Poitiers","country":"France","geoPoint":{"lat":46.58261,"lon":0.34348}},{"facility":"Research Site","city":"Rennes","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"Research Site","city":"Rouen","country":"France","geoPoint":{"lat":49.44313,"lon":1.09932}},{"facility":"Research Site","city":"Strasbourg","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Research Site","city":"Augsburg","country":"Germany","geoPoint":{"lat":48.37154,"lon":10.89851}},{"facility":"Research Site","city":"Berlin","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Research Site","city":"Cologne","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Research Site","city":"Essen","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Research Site","city":"Freiburg im Breisgau","country":"Germany","geoPoint":{"lat":47.9959,"lon":7.85222}},{"facility":"Research Site","city":"Gauting","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"Research Site","city":"Göttingen","country":"Germany","geoPoint":{"lat":51.53443,"lon":9.93228}},{"facility":"Research Site","city":"Großhansdorf","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Research Site","city":"Halle-Dölau","country":"Germany"},{"facility":"Research Site","city":"Hamburg","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Research Site","city":"Heidelberg","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Research Site","city":"Löwenstein","country":"Germany","geoPoint":{"lat":49.09558,"lon":9.38}},{"facility":"Research Site","city":"Magdeburg","country":"Germany","geoPoint":{"lat":52.13129,"lon":11.63189}},{"facility":"Research Site","city":"Mainz","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"Research Site","city":"München","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}},{"facility":"Research Site","city":"Stralsund","country":"Germany","geoPoint":{"lat":54.30911,"lon":13.0818}},{"facility":"Research Site","city":"Wuppertal","country":"Germany","geoPoint":{"lat":51.25627,"lon":7.14816}},{"facility":"Research Site","city":"Honh Kong","country":"Hong Kong"},{"facility":"Research Site","city":"Budapest","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Nyiregyháza","country":"Hungary"},{"facility":"Research Site","city":"Székesfehérvár","country":"Hungary","geoPoint":{"lat":47.18995,"lon":18.41034}},{"facility":"Research Site","city":"Szombathely","country":"Hungary","geoPoint":{"lat":47.23088,"lon":16.62155}},{"facility":"Research Site","city":"Törökbálint","country":"Hungary","geoPoint":{"lat":47.42931,"lon":18.91356}},{"facility":"Research Site","city":"Zalegerzeg-Pózva","country":"Hungary"},{"facility":"Research Site","city":"Dublin","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"Research Site","city":"Bologna","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"facility":"Research Site","city":"Carpi","country":"Italy","geoPoint":{"lat":44.78237,"lon":10.8777}},{"facility":"Research Site","city":"Milan","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Research Site","city":"Rome","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Research Site","city":"Rozzano-Milano","country":"Italy"},{"facility":"Research Site","city":"Treviglio","country":"Italy","geoPoint":{"lat":45.52081,"lon":9.59102}},{"facility":"Research Site","city":"Mexico City","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Research Site","city":"Monterrey","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"Research Site","city":"Amsterdam","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Research Site","city":"Nieuwegeln","country":"Netherlands"},{"facility":"Research Site","city":"Zwolle","country":"Netherlands","geoPoint":{"lat":52.5125,"lon":6.09444}},{"facility":"Research Site","city":"Bydgoszcz","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Research Site","city":"Olsztyn","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Research Site","city":"Otwock","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"Research Site","city":"Posnan","country":"Poland"},{"facility":"Research Site","city":"Warsaw","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Research Site","city":"Wroclaw","country":"Poland","geoPoint":{"lat":51.10286,"lon":17.03006}},{"facility":"Research Site","city":"Moscow","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Research Site","city":"Saint Petersburg","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Research Site","city":"Singapore","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Research Site","city":"Banská Bystrica","country":"Slovakia","geoPoint":{"lat":48.73947,"lon":19.14932}},{"facility":"Research Site","city":"Bratislava","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"facility":"Research Site","city":"Nitra-Zobor","country":"Slovakia"},{"facility":"Research Site","city":"Poprad","country":"Slovakia","geoPoint":{"lat":49.06144,"lon":20.29798}},{"facility":"Research Site","city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Research Site","city":"Barakaldo (Bilbao)","country":"Spain","geoPoint":{"lat":43.29639,"lon":-2.98813}},{"facility":"Research Site","city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Donostia / San Sebastian","country":"Spain","geoPoint":{"lat":43.31283,"lon":-1.97499}},{"facility":"Research Site","city":"Elche Alicante","country":"Spain"},{"facility":"Research Site","city":"Granollers","country":"Spain","geoPoint":{"lat":41.60797,"lon":2.28773}},{"facility":"Research Site","city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Pamplona","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"facility":"Research Site","city":"Pontevedra","country":"Spain","geoPoint":{"lat":42.431,"lon":-8.64435}},{"facility":"Research Site","city":"Santander","country":"Spain","geoPoint":{"lat":43.46589,"lon":-3.80493}},{"facility":"Research Site","city":"Terrassa","country":"Spain","geoPoint":{"lat":41.56667,"lon":2.01667}},{"facility":"Research Site","city":"Valencia","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Research Site","city":"Stockholm","country":"Sweden","geoPoint":{"lat":59.32938,"lon":18.06871}},{"facility":"Research Site","city":"Uppsala","country":"Sweden","geoPoint":{"lat":59.85882,"lon":17.63889}},{"facility":"Research Site","city":"Bern","country":"Switzerland","geoPoint":{"lat":46.94809,"lon":7.44744}},{"facility":"Research Site","city":"Thun","country":"Switzerland","geoPoint":{"lat":46.75118,"lon":7.62166}},{"facility":"Research Site","city":"Zurich","country":"Switzerland","geoPoint":{"lat":47.36667,"lon":8.55}},{"facility":"Research Site","city":"Taipei","state":"Tao Yuan County","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Research Site","city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Research Site","city":"Ankara","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Research Site","city":"Dnipropetrovsk","country":"Ukraine","geoPoint":{"lat":48.46664,"lon":35.04066}},{"facility":"Research Site","city":"Kharkiv","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"facility":"Research Site","city":"Kyiv","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Research Site","city":"Lviv","country":"Ukraine","geoPoint":{"lat":49.83826,"lon":24.02324}},{"facility":"Research Site","city":"Poltava","country":"Ukraine","geoPoint":{"lat":49.58925,"lon":34.55367}},{"facility":"Research Site","city":"Sumy","country":"Ukraine","geoPoint":{"lat":50.91741,"lon":34.79906}},{"facility":"Research Site","city":"Ternopil","country":"Ukraine","geoPoint":{"lat":49.55404,"lon":25.59067}},{"facility":"Research Site","city":"Uzhhorod","country":"Ukraine","geoPoint":{"lat":48.6242,"lon":22.2947}},{"facility":"Research Site","city":"Aberdeen","country":"United Kingdom","geoPoint":{"lat":57.14369,"lon":-2.09814}},{"facility":"Research Site","city":"Bristol","country":"United Kingdom","geoPoint":{"lat":51.45523,"lon":-2.59665}},{"facility":"Research Site","city":"Edinburgh","country":"United Kingdom","geoPoint":{"lat":55.95206,"lon":-3.19648}},{"facility":"Research Site","city":"Leicester","country":"United Kingdom","geoPoint":{"lat":52.6386,"lon":-1.13169}},{"facility":"Research Site","city":"London","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Research Site","city":"Newcastle upon Tyne","country":"United Kingdom","geoPoint":{"lat":54.97328,"lon":-1.61396}},{"facility":"Research Site","city":"Poole","country":"United Kingdom","geoPoint":{"lat":50.71429,"lon":-1.98458}},{"facility":"Research Site","city":"Sutton","country":"United Kingdom","geoPoint":{"lat":51.35,"lon":-0.2}},{"facility":"Research Site","city":"Wolverhampton","country":"United Kingdom","geoPoint":{"lat":52.58547,"lon":-2.12296}}]},"referencesModule":{"references":[{"pmid":"19410716","type":"RESULT","citation":"Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9."},{"pmid":"22498112","type":"DERIVED","citation":"Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Eberhardt WE, de Marinis F, Heeger S, Goddemeier T, O'Byrne KJ, Gatzemeier U. Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. Lung Cancer. 2012 Aug;77(2):376-82. doi: 10.1016/j.lungcan.2012.03.010. Epub 2012 Apr 11."},{"pmid":"22056021","type":"DERIVED","citation":"Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Storkel S, Schumacher KM, von Heydebreck A, Celik I, O'Byrne KJ. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012 Jan;13(1):33-42. doi: 10.1016/S1470-2045(11)70318-7. Epub 2011 Nov 4."},{"pmid":"21782507","type":"DERIVED","citation":"O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, Hotko Y, Kortsik C, Paz-Ares L, Pereira JR, von Pawel J, Ramlau R, Roh JK, Yu CT, Stroh C, Celik I, Schueler A, Pirker R. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol. 2011 Aug;12(8):795-805. doi: 10.1016/S1470-2045(11)70189-9. Epub 2011 Jul 22."},{"pmid":"21169060","type":"DERIVED","citation":"Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt WE, Paz-Ares L, Schumacher KM, Goddemeier T, O'Byrne KJ, Pirker R. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol. 2011 Jan;12(1):30-7. doi: 10.1016/S1470-2045(10)70278-3. Epub 2010 Dec 17."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Enrolled: 1,861 after consent to epidermal growth factor receptor (EGFR) assessment; 603 excluded (mainly non-fulfillment of inclusion or exclusion criteria). 1,258 screened for eligibility after consent for study procedures; 143 excluded (mainly non-fulfillment of inclusion or exclusion criteria). 1,125 subjects randomized.","recruitmentDetails":"First/last subject (informed consent): October 2004/January 2006. Clinical data cut-off: 18 July 2007. Last subject completed 16 May 2012. Subjects randomized at 155 centers; Asia/Australia: 21; Europe: 120; South America: 14.","groups":[{"id":"FG000","title":"Cetuximab Plus Chemotherapy","description":"cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\\^2 initial dose and 250mg/m\\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."},{"id":"FG001","title":"Chemotherapy Alone","description":"cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Intent To Treat (ITT) Population","numSubjects":"557"},{"groupId":"FG001","comment":"ITT Population","numSubjects":"568"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"557"},{"groupId":"FG001","numSubjects":"568"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cetuximab Plus Chemotherapy","description":"cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\\^2 initial dose and 250mg/m\\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."},{"id":"BG001","title":"Chemotherapy Alone","description":"cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"557"},{"groupId":"BG001","value":"568"},{"groupId":"BG002","value":"1125"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59","lowerLimit":"18","upperLimit":"78"},{"groupId":"BG001","value":"60","lowerLimit":"20","upperLimit":"83"},{"groupId":"BG002","value":"59","lowerLimit":"18","upperLimit":"83"}]}]}]},{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"<18 years","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]},{"title":"Between 18 and 65 years","categories":[{"measurements":[{"groupId":"BG000","value":"385"},{"groupId":"BG001","value":"389"},{"groupId":"BG002","value":"774"}]}]},{"title":">=65 years","categories":[{"measurements":[{"groupId":"BG000","value":"172"},{"groupId":"BG001","value":"179"},{"groupId":"BG002","value":"351"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"172"},{"groupId":"BG001","value":"163"},{"groupId":"BG002","value":"335"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"385"},{"groupId":"BG001","value":"405"},{"groupId":"BG002","value":"790"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Australia","categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"43"}]}]},{"title":"Hong Kong","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}]},{"title":"Singapore","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"10"}]}]},{"title":"Korea, Republic of","categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"54"}]}]},{"title":"Taiwan","categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"43"}]}]},{"title":"Austria","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"16"}]}]},{"title":"Belgium","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"13"}]}]},{"title":"Bulgaria","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"24"}]}]},{"title":"Czech Republic","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"29"}]}]},{"title":"France","categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"50"}]}]},{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"88"},{"groupId":"BG002","value":"179"}]}]},{"title":"Hungary","categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"44"}]}]},{"title":"Ireland","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}]}]},{"title":"Netherlands","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"20"}]}]},{"title":"Poland","categories":[{"measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"109"}]}]},{"title":"Portugal","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]}]},{"title":"Russian Federation","categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"39"}]}]},{"title":"Slovakia","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"20"}]}]},{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"29"}]}]},{"title":"Sweden","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"9"}]}]},{"title":"Switzerland","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"16"}]}]},{"title":"Turkey","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]},{"title":"United Kingdom","categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"44"}]}]},{"title":"Ukraine","categories":[{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"127"}]}]},{"title":"Chile","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"26"}]}]},{"title":"Italy","categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"41"}]}]},{"title":"Argentina","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"}]}]},{"title":"Mexico","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"}]}]},{"title":"Brazil","categories":[{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"99"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival Time (OS)","description":"Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007","groups":[{"id":"OG000","title":"Cetuximab Plus Chemotherapy","description":"cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\\^2 initial dose and 250mg/m\\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."},{"id":"OG001","title":"Chemotherapy Alone","description":"cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"557"},{"groupId":"OG001","value":"568"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","lowerLimit":"9.4","upperLimit":"12.4"},{"groupId":"OG001","value":"10.1","lowerLimit":"9.1","upperLimit":"10.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Primary efficacy analysis: To test equality of OS time between treatment groups, applying the two-sided stratified log-rank test (Stage IIIb vs IV, ECOG 0/1 vs 2) (α=5%).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0441","statisticalMethod":"Stratified Log Rank","ciPctValue":"95","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"Progression-free Survival Time","description":"Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause.\n\nOnly deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007","groups":[{"id":"OG000","title":"Cetuximab Plus Chemotherapy","description":"cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\\^2 initial dose and 250mg/m\\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."},{"id":"OG001","title":"Chemotherapy Alone","description":"cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"557"},{"groupId":"OG001","value":"568"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"4.2","upperLimit":"5.3"},{"groupId":"OG001","value":"4.8","lowerLimit":"4.4","upperLimit":"5.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"To test equality of progression free survival time between treatment groups, applying the two-sided stratified log-rank test (α=5%).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3869","statisticalMethod":"Stratified Log Rank","ciPctValue":"95","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"Best Overall Response Rate","description":"The best overall response rate is defined as the proportion of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007","groups":[{"id":"OG000","title":"Cetuximab Plus Chemotherapy","description":"cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\\^2 initial dose and 250mg/m\\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."},{"id":"OG001","title":"Chemotherapy Alone","description":"cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"557"},{"groupId":"OG001","value":"568"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","lowerLimit":"32.4","upperLimit":"40.6"},{"groupId":"OG001","value":"29.2","lowerLimit":"25.5","upperLimit":"33.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The best overall response rate was compared in the Cochran-Mantel-Haenszel test (two-sided with α=5%).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0101","statisticalMethod":"Cochran-Mantel-Haenszel","ciPctValue":"95","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"Disease Control Rate","description":"The disease control rate is defined as the proportion of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria).","populationDescription":"ITT","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007","groups":[{"id":"OG000","title":"Cetuximab Plus Chemotherapy","description":"cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\\^2 initial dose and 250mg/m\\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."},{"id":"OG001","title":"Chemotherapy Alone","description":"cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"557"},{"groupId":"OG001","value":"568"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","lowerLimit":"68.6","upperLimit":"76.2"},{"groupId":"OG001","value":"71.5","lowerLimit":"67.6","upperLimit":"75.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The disease control rate was compared in the Cochran-Mantel-Haenszel test (two-sided with α=5%).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6801","statisticalMethod":"Cochran-Mantel-Haenszel","ciPctValue":"95","ciNumSides":"TWO_SIDED"}]},{"type":"SECONDARY","title":"Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status","description":"Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.","populationDescription":"670 subjects completed (348 in the cetuximab + chemotherapy arm and 322 in the chemotherapy alone arm) at least 1 evaluable QLQ-C30 questionnaire and were included in the Evaluable population. Numbers at each timepoint were (Cetuximab + chemotherapy/Chemotherapy alone, respectively): baseline 278/274; cycle 3 184/153; 6 month 102/96","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"at baseline, at cycle 3, at month 6, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007","groups":[{"id":"OG000","title":"Cetuximab Plus Chemotherapy","description":"cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\\^2 initial dose and 250mg/m\\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."},{"id":"OG001","title":"Chemotherapy Alone","description":"cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"322"}]}],"classes":[{"title":"At baseline","categories":[{"measurements":[{"groupId":"OG000","value":"45.72","spread":"2.164"},{"groupId":"OG001","value":"46.36","spread":"2.138"}]}]},{"title":"At cycle 3","categories":[{"measurements":[{"groupId":"OG000","value":"48.33","spread":"2.325"},{"groupId":"OG001","value":"51.55","spread":"2.464"}]}]},{"title":"At month 6","categories":[{"measurements":[{"groupId":"OG000","value":"54.71","spread":"2.729"},{"groupId":"OG001","value":"52.92","spread":"2.787"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Assessment (EORTC QLQ-C30) Social Functioning","description":"Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.","populationDescription":"670 subjects completed (348 in the cetuximab + chemotherapy arm and 322 in the chemotherapy alone arm) at least 1 evaluable QLQ-C30 questionnaire and were included in the Evaluable population. Numbers at each timepoint were (Cetuximab + chemotherapy/Chemotherapy alone, respectively): baseline 280/275; cycle 3 185/153; 6 month 101/97","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"scores on a scale","timeFrame":"at baseline, at cycle 3, at month 6, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007","groups":[{"id":"OG000","title":"Cetuximab Plus Chemotherapy","description":"cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\\^2 initial dose and 250mg/m\\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."},{"id":"OG001","title":"Chemotherapy Alone","description":"cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"348"},{"groupId":"OG001","value":"322"}]}],"classes":[{"title":"At baseline","categories":[{"measurements":[{"groupId":"OG000","value":"66.17","spread":"2.836"},{"groupId":"OG001","value":"64.73","spread":"2.825"}]}]},{"title":"At cycle 3","categories":[{"measurements":[{"groupId":"OG000","value":"58.05","spread":"2.995"},{"groupId":"OG001","value":"67.13","spread":"3.138"}]}]},{"title":"At month 6","categories":[{"measurements":[{"groupId":"OG000","value":"67.36","spread":"3.449"},{"groupId":"OG001","value":"66.47","spread":"3.515"}]}]}]},{"type":"SECONDARY","title":"A Population Pharmacokinetic (PK) Analysis for Cetuximab in Non-Small Cell Lung Cancer (NSCLC) - Serum Cetuximab Concentrations","description":"Population PK analysis was conducted using non-linear mixed effects modeling (NONMEM) software, integrating the PK data from this study and the Phase II study EMR 62 202-011.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ug/mL","timeFrame":"Week 1, Day 1: baseline and end of infusion; Week 7, Day 43: within 12 h after cetuximab administration.","groups":[{"id":"OG000","title":"Cetuximab Concentration at End of Infusion Week 1"},{"id":"OG001","title":"Cetuximab Concentration Before Infusion Week 7"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"454"},{"groupId":"OG001","value":"298"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"223.1","spread":"64.6"},{"groupId":"OG001","value":"51.5","spread":"33.1"}]}]}]},{"type":"SECONDARY","title":"Safety - Number of Patients Experiencing Any Adverse Event","description":"Please refer to Adverse Events section for further details","populationDescription":"Safety Population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"time from first dose up to 30 after last dose of study treatment, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007","groups":[{"id":"OG000","title":"Cetuximab Plus Chemotherapy","description":"cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\\^2 initial dose and 250mg/m\\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."},{"id":"OG001","title":"Chemotherapy Alone","description":"cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"548"},{"groupId":"OG001","value":"562"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"545"},{"groupId":"OG001","value":"549"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Time from first dose up to 30 days after the last dose of study treatment.","description":"Treatment-emergent adverse events were defined as those with onset occurring at or after the first dosing day of study medication and up to 30 days after the last administration of any study drug or the clinical cut-off date.","eventGroups":[{"id":"EG000","title":"Cetuximab Plus Chemotherapy","description":"cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\\^2 initial dose and 250mg/m\\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects.","seriousNumAffected":325,"seriousNumAtRisk":548,"otherNumAffected":532,"otherNumAtRisk":548},{"id":"EG001","title":"Chemotherapy Alone","description":"cisplatin 80mg/m\\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.\n\nSafety population: includes all treated subjects.","seriousNumAffected":244,"seriousNumAtRisk":562,"otherNumAffected":537,"otherNumAtRisk":562}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":548},{"groupId":"EG001","numAffected":12,"numAtRisk":562}]},{"term":"Febrile bone marrow aplasia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":96,"numAtRisk":548},{"groupId":"EG001","numAffected":67,"numAtRisk":562}]},{"term":"Granulocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":548},{"groupId":"EG001","numAffected":8,"numAtRisk":562}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":47,"numAtRisk":548},{"groupId":"EG001","numAffected":33,"numAtRisk":562}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Arrhythmia supraventricular","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":4,"numAtRisk":562}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Cardiogenic shock","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Cardiopulmonary failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":548},{"groupId":"EG001","numAffected":3,"numAtRisk":562}]},{"term":"Left ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Microvascular angina","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Right ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Tricuspid valve incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Ventricular fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Tracheo-oesophageal fistula","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Deafness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":548},{"groupId":"EG001","numAffected":8,"numAtRisk":562}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Anal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":548},{"groupId":"EG001","numAffected":6,"numAtRisk":562}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":548},{"groupId":"EG001","numAffected":5,"numAtRisk":562}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Faecaloma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Ileus paralytic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":548},{"groupId":"EG001","numAffected":5,"numAtRisk":562}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":548},{"groupId":"EG001","numAffected":14,"numAtRisk":562}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":548},{"groupId":"EG001","numAffected":6,"numAtRisk":562}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Drug interaction","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":548},{"groupId":"EG001","numAffected":4,"numAtRisk":562}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Multi-organ failure","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":548},{"groupId":"EG001","numAffected":6,"numAtRisk":562}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Hepatic pain","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Drug hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Serum sickness","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Bacterial sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Brain abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Bronchitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Catheter related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Central line infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Clostridial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Dengue fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Febrile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Laryngotracheo bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Neutropenic infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":548},{"groupId":"EG001","numAffected":5,"numAtRisk":562}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":548},{"groupId":"EG001","numAffected":5,"numAtRisk":562}]},{"term":"Parotitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Peritonsillar abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Pharyngotonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":548},{"groupId":"EG001","numAffected":13,"numAtRisk":562}]},{"term":"Pneumonia necrotising","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Pneumonia streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Pyothorax","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":548},{"groupId":"EG001","numAffected":3,"numAtRisk":562}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Aspiration bronchial","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":548},{"groupId":"EG001","numAffected":4,"numAtRisk":562}]},{"term":"Blood glucose abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Blood potassium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Karnofsky scale worsened","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Pulmonary arterial pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":548},{"groupId":"EG001","numAffected":9,"numAtRisk":562}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Fluid overload","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Hypercreatininaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Metastases to heart","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Testis cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Altered state of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Cerebellar syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Cerebral artery embolism","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":5,"numAtRisk":562}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Coma","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Coordination abnormal","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Embolic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Hemiplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Horner's syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Monoparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Nervous system disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Paraparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Paraplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Speech disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Syncope vasovagal","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Transverse sinus thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":548},{"groupId":"EG001","numAffected":4,"numAtRisk":562}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Mental disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":548},{"groupId":"EG001","numAffected":6,"numAtRisk":562}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Acute pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Apnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":548},{"groupId":"EG001","numAffected":13,"numAtRisk":562}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":548},{"groupId":"EG001","numAffected":6,"numAtRisk":562}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Lung infiltration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":4,"numAtRisk":562}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":3,"numAtRisk":562}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":548},{"groupId":"EG001","numAffected":13,"numAtRisk":562}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":548},{"groupId":"EG001","numAffected":9,"numAtRisk":562}]},{"term":"Respiratory tract haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Arterial thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Axillary vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":548},{"groupId":"EG001","numAffected":3,"numAtRisk":562}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Iliac artery occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Jugular vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Pelvic venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Superior vena caval occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Varicose vein","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Vascular fragility","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Vasculitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Vena cava thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Visceral arterial ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]}],"otherEvents":[{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":302,"numAtRisk":548},{"groupId":"EG001","numAffected":324,"numAtRisk":562}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":226,"numAtRisk":548},{"groupId":"EG001","numAffected":264,"numAtRisk":562}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":176,"numAtRisk":548},{"groupId":"EG001","numAffected":155,"numAtRisk":562}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":36,"numAtRisk":548},{"groupId":"EG001","numAffected":32,"numAtRisk":562}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":548},{"groupId":"EG001","numAffected":30,"numAtRisk":562}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":49,"numAtRisk":548},{"groupId":"EG001","numAffected":55,"numAtRisk":562}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":548},{"groupId":"EG001","numAffected":6,"numAtRisk":562}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":291,"numAtRisk":548},{"groupId":"EG001","numAffected":303,"numAtRisk":562}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":214,"numAtRisk":548},{"groupId":"EG001","numAffected":225,"numAtRisk":562}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":204,"numAtRisk":548},{"groupId":"EG001","numAffected":189,"numAtRisk":562}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":126,"numAtRisk":548},{"groupId":"EG001","numAffected":103,"numAtRisk":562}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":85,"numAtRisk":548},{"groupId":"EG001","numAffected":27,"numAtRisk":562}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":72,"numAtRisk":548},{"groupId":"EG001","numAffected":72,"numAtRisk":562}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":68,"numAtRisk":548},{"groupId":"EG001","numAffected":55,"numAtRisk":562}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":45,"numAtRisk":548},{"groupId":"EG001","numAffected":37,"numAtRisk":562}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":548},{"groupId":"EG001","numAffected":7,"numAtRisk":562}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":202,"numAtRisk":548},{"groupId":"EG001","numAffected":181,"numAtRisk":562}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":112,"numAtRisk":548},{"groupId":"EG001","numAffected":80,"numAtRisk":562}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":90,"numAtRisk":548},{"groupId":"EG001","numAffected":96,"numAtRisk":562}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":70,"numAtRisk":548},{"groupId":"EG001","numAffected":70,"numAtRisk":562}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":56,"numAtRisk":548},{"groupId":"EG001","numAffected":23,"numAtRisk":562}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":35,"numAtRisk":548},{"groupId":"EG001","numAffected":19,"numAtRisk":562}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":548},{"groupId":"EG001","numAffected":29,"numAtRisk":562}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":548},{"groupId":"EG001","numAffected":39,"numAtRisk":562}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":46,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":548},{"groupId":"EG001","numAffected":16,"numAtRisk":562}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":75,"numAtRisk":548},{"groupId":"EG001","numAffected":50,"numAtRisk":562}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":47,"numAtRisk":548},{"groupId":"EG001","numAffected":49,"numAtRisk":562}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":36,"numAtRisk":548},{"groupId":"EG001","numAffected":26,"numAtRisk":562}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":208,"numAtRisk":548},{"groupId":"EG001","numAffected":202,"numAtRisk":562}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":75,"numAtRisk":548},{"groupId":"EG001","numAffected":49,"numAtRisk":562}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":54,"numAtRisk":548},{"groupId":"EG001","numAffected":27,"numAtRisk":562}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":548},{"groupId":"EG001","numAffected":10,"numAtRisk":562}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":53,"numAtRisk":548},{"groupId":"EG001","numAffected":32,"numAtRisk":562}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":548},{"groupId":"EG001","numAffected":44,"numAtRisk":562}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":548},{"groupId":"EG001","numAffected":37,"numAtRisk":562}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":548},{"groupId":"EG001","numAffected":22,"numAtRisk":562}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":548},{"groupId":"EG001","numAffected":28,"numAtRisk":562}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":82,"numAtRisk":548},{"groupId":"EG001","numAffected":57,"numAtRisk":562}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":79,"numAtRisk":548},{"groupId":"EG001","numAffected":60,"numAtRisk":562}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":49,"numAtRisk":548},{"groupId":"EG001","numAffected":46,"numAtRisk":562}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":40,"numAtRisk":548},{"groupId":"EG001","numAffected":27,"numAtRisk":562}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":548},{"groupId":"EG001","numAffected":33,"numAtRisk":562}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":58,"numAtRisk":548},{"groupId":"EG001","numAffected":49,"numAtRisk":562}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":101,"numAtRisk":548},{"groupId":"EG001","numAffected":95,"numAtRisk":562}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":97,"numAtRisk":548},{"groupId":"EG001","numAffected":80,"numAtRisk":562}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":45,"numAtRisk":548},{"groupId":"EG001","numAffected":24,"numAtRisk":562}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":548},{"groupId":"EG001","numAffected":14,"numAtRisk":562}]},{"term":"Pharyngolaryngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":548},{"groupId":"EG001","numAffected":20,"numAtRisk":562}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":548},{"groupId":"EG001","numAffected":15,"numAtRisk":562}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":249,"numAtRisk":548},{"groupId":"EG001","numAffected":17,"numAtRisk":562}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":107,"numAtRisk":548},{"groupId":"EG001","numAffected":107,"numAtRisk":562}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":76,"numAtRisk":548},{"groupId":"EG001","numAffected":9,"numAtRisk":562}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":75,"numAtRisk":548},{"groupId":"EG001","numAffected":1,"numAtRisk":562}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":64,"numAtRisk":548},{"groupId":"EG001","numAffected":13,"numAtRisk":562}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":38,"numAtRisk":548},{"groupId":"EG001","numAffected":2,"numAtRisk":562}]},{"term":"Skin fissures","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":548},{"groupId":"EG001","numAffected":0,"numAtRisk":562}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":48,"numAtRisk":548},{"groupId":"EG001","numAffected":44,"numAtRisk":562}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":40,"numAtRisk":548},{"groupId":"EG001","numAffected":27,"numAtRisk":562}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":548},{"groupId":"EG001","numAffected":23,"numAtRisk":562}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"title":"Merck KGaA Communication Center","organization":"Merck KGaA","email":"service@merckgroup.com","phone":"+49-6151-72-5200"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D008175","term":"Lung Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068818","term":"Cetuximab"},{"id":"D002945","term":"Cisplatin"},{"id":"D000077235","term":"Vinorelbine"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D014748","term":"Vinca Alkaloids"},{"id":"D046948","term":"Secologanin Tryptamine Alkaloids"},{"id":"D026121","term":"Indole Alkaloids"},{"id":"D000470","term":"Alkaloids"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D007211","term":"Indoles"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D054836","term":"Indolizidines"},{"id":"D007212","term":"Indolizines"}]}},"hasResults":true}